Cryptosporidiosis has been recognized as one of the leading causes of morbidity and mortality from diarrhea in children under 5 years of age in low-resource settings. Despite the magnitude and significance of the problem, only a single drug is approved to treat Cryptosporidium infection, and new therapies are urgently needed.

The third Symposium on Innovative Therapeutics for Cryptosporidium puts the spotlight on Crypto. Similar to the first two meetings hosted by PATH in San Francisco, California (2016) and Seattle, Washington (2018), this convening assembles leading researchers to present and discuss the current state of work on Crypto— from early discovery to clinical development and commercialization, veterinary medicine, diagnostics, and vaccines. Our goal is to share research, highlight opportunities for collaboration, and spark innovation toward making new and improved therapies a reality. This document summarizes the event's scientific program.